Propoxyphene hydrochloride. A critical review.
D000700:Analgesics / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002110:Caffeine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003061:Codeine / Q000627:therapeutic use; D011431:Dextropropoxyphene / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006261:Headache / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use; D008614:Meperidine / Q000627:therapeutic use; D009020:Morphine / Q000627:therapeutic use; D009269:Nalorphine / Q000627:therapeutic use; D009294:Narcotics / Q000627:therapeutic use; D010146:Pain; D010510:Periodontal Diseases / Q000188:drug therapy; D010615:Phenacetin / Q000627:therapeutic use; D010919:Placebos; D011182:Postoperative Care; D011247:Pregnancy; D011644:Puerperal Disorders / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome; D019966:Substance-Related Disorders; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000700:Analgesics; D007211:Indoles; D007546:Isoquinolines; D009294:Narcotics; D010919:Placebos; D014149:Tranquilizing Agents; D002110:Caffeine; D009020:Morphine; D008614:Meperidine; D010615:Phenacetin; D001241:Aspirin; D011431:Dextropropoxyphene; D009269:Nalorphine; D003061:Codeine